Transvaginal Ultrasonography Guided Embryo Transfer

Could Transvaginal Ultrasonography Guided Embryo Transfer Improves Pregnancy Outcome in Obese Patients Undergoing Intracytoplasmic Sperm Inoculation? Randomized Controlled Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03473028

Enrollment

800

Registered

2018-03-21

Start date

2018-04-01

Completion date

2021-03-04

Last updated

2021-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Keywords

obesity, embryo transfer, invitro fertilization

Brief summary

to evaluate the value of using transvaginal ultrasound guided embryo transfer in obese patients undergoing in vitro fertilization.

Detailed description

The 800 participants with body mass index more than 30kg/m2 were randomly allocated to two groups of equal size using an automated web-based randomization system. The first group 400 patient undergoing the transabdominal-guided embryo transfer, the second group 400 patient undergoing transvaginal-guided embryo transfer.

Interventions

PROCEDUREtransabdominal ultrasound guided embryo transfer

400 female with body mass index more than 30undergo transabdominal ultrasound guided embryo transfer

PROCEDUREtransvaginal ultrasound guided embryo transfer

400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

randomized controlled trial

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 40 Years

Healthy volunteers

Inclusion criteria

* BMI more than 35, good ovarian reserve, unexplained infertility more than 3 years.

Exclusion criteria

* severe male factor of infertility,uterine factor of infertility excluded by ultrasonography and hysteroscopy ,ovarian endometrioma or patients with poly cystic ovary syndrome, obesity caused by abnormal endocrine function (thyroid or adrenal disorder)

Design outcomes

Primary

Measure	Time frame	Description
clinical pregnancy rate'	4 weeks following embryo transfer	the presence of at least one intrauterine gestational sac with viable fetus.

Secondary

Measure	Time frame	Description
live birth rate	immediately following delivery	delivery of a living baby

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026